Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.


A broad-spectrum antifungal agent, C26H28Cl2N4O4, administered as a topical treatment or as a second-line oral treatment for a variety of fungal infections.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n ketoconazol m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
These shampoos contain dandruff fighters like pyrithione zinc (Head & Shoulders[R]), salicylic acid (Neutrogena T/Sal[R]), selenium sulfide (Selsun Blue[R]), coal tar (Neutrogena T/Gel[R]), and ketoconazole (Nizoral[R]).
The Committee considered that this constitutes a clinically relevant advantage." The medications ketoconazole, metyropone and pasireotide are approved in the EU for the treatment of one or more aetologies of Cushing's syndrome.
Keywords: Pityriasis versicolor, susceptibility, disc diffusion, ketoconazole, fluconazole, miconazole, Malassezia spp.
Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor.
Ketoconazole and posaconazole are both members of the azole antifungal family.
As part of the new agreement, the featured products include Stratford's KETO-C shampoo, flush, spray and wipes which help control dermatological issues which respond to ketoconazole and chlorhexidine.
glabrata showed the lowest susceptibility to fluconazole and miconazole, and the highest to ketoconazole. C.
The patient's rash failed to improve over the following 4 months, despite the intermittent use of clotrimazole 1% cream and ketoconazole 2% cream.
In 2013, the United States Food and Drug Administration (US FDA) and the European Medicines Agency's Committee on Medical Products for Human Use (EMA-CHMP) concurrently issued safety warnings and limited the use of oral ketoconazole because of its association with increased risk of inducing hepatic injury, risk of drug interactions, and increased risk of adrenal insufficiency [1, 2].
Terbinafine and ketoconazole were evaluated in concentrations from 0.0234 to 480 [micro]g m[L.sup.-1] and from 0.0313 to 640[micro]g m[L.sup.-1], respectively, in RPMI-1640 medium buffered with MOPS [19, 20].